KRYS Krystal Biotech, Inc. Insider Trading

Suma Krishnan (President, R&D) sold 25,000 shares for $7.7M via scheduled 10b5-1 plan on 2026-06-04

Suma Krishnan executed 11 separate sales totaling 25,000 shares for $7,702,825.22 on 2026-06-04 at a blended average price of $308.11, reducing his holdings from 1.40M to 1.38M shares (-1.8%). This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, making it a scheduled execution rather than a discretionary trade. The sell occurred near KRYS's 52-week high of $319.48 (current price $301.00, down 5.8% from peak), and in the context of his same-ticker history at KRYS, prior sales in March 2026 showed modest 30-day returns (ranging -1.4% to +1.4%) but consistently positive 90-day outcomes (+10.8% to +14.0%). With KRYS trading at a 39.45 P/E and demonstrating strong fundamentals (annual revenue growth of +33.9%, latest quarter revenue of $116.4M and net income of $55.9M), the liquidation reflects execution of a pre-planned schedule rather than a signal about conviction in the company's trajectory.

KRYS CEO Krishnan sold 25,000 shares for $7.7M (avg $308.12) via scheduled 10b5-1 plan on 2026-06-04

Krish S Krishnan, President and CEO of Krystal Biotech, executed 11 separate sales totaling 25,000 shares for $7,702,983.82 on 2026-06-04, reducing his holdings from 1,475,253 shares to 1,450,253 shares (a -1.7% net change). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning it was scheduled rather than discretionary. The blended average sale price was $308.12, slightly above the current price of $301.00. The company's fundamentals show strong growth (annual revenue growth of +33.9%) and profitability (net income of $55,932,000.00 on revenue of $116,357,000.00 in the latest quarter), though the P/E ratio of 39.45 reflects investor expectations. Given the scheduled nature of the transaction under a 10b5-1 plan, this sale does not convey timing-dependent signals; it represents predetermined portfolio activity that proceeded regardless of current market conditions.